Feasibility of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults (ChaREx)

August 12, 2026 updated by: Nuzha Amjad, The University of Texas Health Science Center, Houston

Feasibility of 24-Weeks of At-Home Chair-Based Resistance Band Training to Improve Balance, Strength, and Bone Density in Older Adults (ChaREx Study)

The purpose of this study is to determine the feasibility of implementing a 24-week at-home chair-based resistance band training intervention, to determine effectiveness of a the a 24-week at-home chair-based resistance band training intervention in improving body composition and to determine the effectiveness of a 24-week at-home chair-based resistance band training intervention in improving physical performance in adults 50 years and older, receiving care at the UT Physicians Center for Healthy Aging.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
11

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • United States
    • Texas
      • Houston, Texas, United States, 77479
        • The University of Texas Health Science Center at Houston

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • English-speaking
  • receive care at the UT Physician Center for Healthy Aging

Exclusion Criteria:

  • inability to provide informed consent on their own
  • presence of obvious signs of cognitive decline
  • a diagnosis of dementia and inability to come to the clinic for the scheduled study visits.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Chair-based resistance band training
Device: THERABand resistance exercise bands
The training will be performed using THERABand resistance exercise bands.Participants will be instructed to perform the exercises twice per week at home, for the 24 weeks duration. Each exercise session will entail 1 set of 15 repetitions of 9 different exercises

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Feasibility as assessed by the number of people who are able to follow the prescribed exercise regimen at least 50 percent of the time
Time Frame: end of study (24 weeks from baseline)
end of study (24 weeks from baseline)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change in body fat
Time Frame: baseline,6-months
This will be assessed using the handheld bioelectrical impedance analysis (BIA) device (Omron HBF-510)
baseline,6-months
Change in bone mineral density (BMD) of the femoral neck and lumbar spine
Time Frame: baseline, 1 year from baseline
This will be assessed by the Dual energy x-ray absorptiometry (DXA)
baseline, 1 year from baseline
Handgrip strength
Time Frame: baseline
This will be assessed using a validated handgrip dynamometer
baseline
Handgrip strength
Time Frame: 1-month
This will be assessed using a validated handgrip dynamometer
1-month
Handgrip strength
Time Frame: 3-months
This will be assessed using a validated handgrip dynamometer
3-months
Handgrip strength
Time Frame: 6-months
This will be assessed using a validated handgrip dynamometer
6-months
60-second balance as assessed by the the Zibrio Stability Pro scale
Time Frame: Baseline
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
Baseline
60-second balance as assessed by the the Zibrio Stability Pro scale
Time Frame: 1-month
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
1-month
60-second balance as assessed by the the Zibrio Stability Pro scale
Time Frame: 3-months
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
3-months
60-second balance as assessed by the the Zibrio Stability Pro scale
Time Frame: 6-months
This is determined by the patient standing on the Zibrio Stability Pro Scale unassisted for one minute and will be measured on a scale of 1 to 9 with lower scores indicating higher risk of fall
6-months
walking gait speed
Time Frame: Baseline
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
Baseline
walking gait speed
Time Frame: 1-month
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
1-month
walking gait speed
Time Frame: 3-months
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
3-months
walking gait speed
Time Frame: 6-months
Gait speed will be assessed over a 6-meter distance measured within a private clinic space. The participant will be instructed to walk at their normal walking pace (as if they were walking throughout the house) and the distance/time will be converted to meters/second.Faster walking speed is related to reduced fall-risk, improved physical function, and greater survival .
6-months
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
Time Frame: Baseline
P1NP is a metabolic marker of bone formation, indicates status of bone loss and a stable or decreased level will be indicating improved metabolism
Baseline
Blood level of pro-collagen type 1 N-telopeptide (P1NP)
Time Frame: 6 months
P1NP is a metabolic marker of bone formation, indicates status of bone loss and a stable or decreased level will be indicating improved metabolism
6 months
Frailty as assessed by the Fried criteria
Time Frame: Baseline
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
Baseline
Frailty as assessed by the Fried criteria
Time Frame: 1-month
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
1-month
Frailty as assessed by the Fried criteria
Time Frame: 3-months
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
3-months
Frailty as assessed by the Fried criteria
Time Frame: 6-months
This consists of 5 items (unintentional weight loss, weakness [low grip strength], slowness low, self-reported exhaustion and low physical activity). Patients who meet 1or 2 of the criteria are described as pre-frail and 3 or more as frail.
6-months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
The University of Texas Health Science Center, Houston

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Nuzha Amjad, MD, The University of Texas Health Science Center, Houston

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 5, 2025

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 7, 2026

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 7, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 1, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 1, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 4, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 14, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 12, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • HSC-MS-24-0485

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings